🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Diagnostic and Therapeutic Targets in Cartilaginous Tumours

Recruitingn/aAges any - anyAllSt. Anne's University Hospital Brno, Czech Republ…
NCT07315542 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study, "Finding new diagnostic and therapeutic targets in cartilaginous tumours," focuses on improving the diagnosis, prognostic stratification, and treatment options for chondroid tumours, particularly chondrosarcoma. Chondrosarcoma is the most common primary malignant bone tumour in adults and is characterized by resistance to chemotherapy and radiotherapy, making accurate diagnosis and optimal surgical management critical. Distinguishing benign cartilage tumours (enchondromas, atypical cartilaginous tumours) from low-grade chondrosarcoma, and differentiating chondrosarcoma from chondroblastic osteosarcoma, remain major diagnostic challenges. The project investigates two key molecular markers: mutations in IDH1/2 genes and non-coding microRNAs (miRNAs). IDH1/2 mutations are frequent in central chondrosarcomas and rare in other mesenchymal tumours, making them promising diagnostic

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria * Histologically confirmed cartilaginous (chondroid) tumour * Diagnosis includes one of the following entities (as available and eligible): * Enchondroma * Atypical cartilaginous tumour / Grade 1 chondrosarcoma (ACT/G1) * Conventional chondrosarcoma (Grade 2-3) * Dedifferentiated chondrosarcoma * Other rare chondrosarcoma variants (e.g., mesenchymal, clear-cell), if present in the cohort * Patients treated and/or followed at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno Exclusion Criteria * Insufficient, degraded, or otherwise unusable tissue samples
💊

What it tests

  • Tumour tissue analysis
  • Molecular validation
  • Liquid biopsy analysis
📍

Where

1 site
First Department of Orthopaedic Surgery, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
Brno, Czechia
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy